TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06421701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK cells
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) on day -5, -4, and -3. Doses of 2×10\^6/kg, 3×10\^6/kg, 4×10\^6/kg anti-CD19 CAR-NK cells will be infused in each group on Day 0, 7, and 14 using the 3 + 3 dose-escalation strategy.
Study: NCT05684367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center-Based Walking Exercise
Description: Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Walking Exercise
Description: Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
Study: NCT05453110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deadlift Form Education
Description: The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deadlift Form Education
Description: The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.
Study: NCT05205382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% nicotine
Description: Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3% nicotine
Description: Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% nicotine
Description: Effects of e-cigarette pods (SREC) with 0% nicotine concentration
Study: NCT05831124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose multivalent pneumococcal conjugate vaccine formulation A
Description: Biological
Study: NCT06324357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine
Study: NCT06602050

Intervention type: OTHER
Intervention: HG and NIF
Description: In mechanically ventilated patients, handgrip strength, the Negative Inspiratory Force (NIF) value obtained via the ventilator, and physical function through various tests will be assessed.
Study: NCT06603051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: Those randomized to the intervention group (Group B) will receive a standard treatment of Cryoneurolysis to their surgical knee within 7-10 days of their scheduled surgery. Treatment nerves for the procedure will include the anterior femoral cutaneous nerve (AFCN), supra-patellar branch of the saphenous nerve (SPBSN) and infra-patellar branch of the saphenous nerve (IPBSN).
Study: NCT06588296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT05803382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06657612

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06605508

Intervention type: PROCEDURE
Intervention: Autologous Adipose Tissue-Derived Stem Cell Injection for Erectile Dysfunction
Description: This intervention involves the use of autologous adipose tissue-derived stem cells (ADSC) to treat erectile dysfunction. The process begins with a minimally invasive liposuction procedure to harvest fat tissue from the participant\&#39;s own body. The harvested fat is then processed to isolate stem cells, which are subsequently injected directly into the erectile tissue of the penis. This approach aims to enhance erectile function by promoting tissue regeneration and improving blood flow. Unlike other treatments for erectile dysfunction, this intervention uses stem cells derived from the participant\&#39;s own fat, which may reduce the risk of immune rejection and offer a novel regenerative therapy option. The treatment is designed to address ED in patients who have not responded adequately to conventional therapies like PDE-5 inhibitors.

Intervention type: PROCEDURE
Intervention: Stem cell-derived Exosomes Injection for Erectile Dysfunction
Description: This intervention involves the use of stem cell-derived exosomes to treat erectile dysfunction. Exosomes are nano-sized extracellular vesicles secreted by stem cells, containing bioactive molecules such as growth factors and signaling proteins that promote tissue repair and regeneration. Unlike therapies requiring the transplantation of live cells, this cell-free approach eliminates the need for invasive harvesting procedures. The exosomes are carefully purified from cultured stem cells and prepared for direct injection into the erectile tissue of the penis. This approach aims to enhance erectile function by stimulating tissue regeneration, reducing inflammation, and improving blood flow. Unlike other treatments for erectile dysfunction, exosome therapy offers a novel regenerative option, potentially benefiting patients who have not responded adequately to conventional therapies such as PDE-5 inhibitors.
Study: NCT06589635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC-189 and Itraconazole
Description: Part 1:~Day 1, fasting condition, 45 mg ADC189, administered orally~Part 2:~Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals.
Study: NCT06588777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified thoracoabdominal nerve block through perichondrial approach (M-TAPA)
Description: transversus abdominis, internal oblique, and external oblique muscles will be identified with a high-frequency (10 MHz) linear probe on the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. A deep angle was given to the costochondral angle at the edge of the 10th costal margin with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. A 22-G, 100-mm block needle will be inserted in the cranial direction using the in-plane technique and the needle tip will be moved to the posterior aspect of the 10th costal cartilage. It is noted that the needle tip never crossed the cranial edge of the 10th costal cartilage
Study: NCT05831124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose multivalent pneumococcal conjugate vaccine formulation B
Description: Biological

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of multivalent pneumococcal conjugate vaccine control
Description: low dose multivalent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose multivalent pneumococcal conjugate vaccine control
Description: multivalent pneumococcal conjugate vaccine
Study: NCT06588777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: using ultrasound guidance (Sonosite turbo M, Bothell, Washington, USA) and a curved ultrasound probe (2.5-7.5 MHz). The probe will be placed in the mid-axillary line between the lower costal margin and the iliac crest in a transverse plane to view all abdominal layers. The probe will be moved towards the posterior axillary line, to reach a point where all three abdominal muscle layers merge to form aponeurosis.~The aponeurosis will then be followed dorsally until the quadratus lumborum muscle is seen deep to transversalis fascia with its attachment to the transverse process of the L4 vertebral body. A 22 G, 100 mm, blunt, insulated nerve block needle will be inserted 1 cm medial to the probe and advanced using the in-plane technique with ultrasound real-time assessment. The injection site will be the junction of transversalis fascia and the anterolateral border of quadratus lumborum muscle
Study: NCT06662058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Audiometric Test
Description: Undergo audiometry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Audiometric Test
Description: Undergo audiometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audiometric Test
Description: Undergo audiometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audiometric Test
Description: Undergo close to home audiometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audiometric Test
Description: Undergo self-administered remote audiometry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study: NCT06663332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.
Study: NCT06589687

Intervention type: OTHER
Intervention: Interview
Description: Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under neuraxial anesthetic.
Study: NCT06590857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101
Description: Ac-225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101
Description: Ac-225
Study: NCT06593769

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: whey-protein microgel
Description: The product used in this study is a liquid 125 mL whey protein microgel (WPM) formulation that will be delivered in a ready-to-drink formulation. The WPM is dairy based and, aside from milk and lactose, no other allergens are present Whey proteins and caseinates are two major fractions of cow milk proteins.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: whey-protein microgel
Description: The product used in this study is a liquid 125 mL whey protein microgel (WPM) formulation that will be delivered in a ready-to-drink formulation. The WPM is dairy based and, aside from milk and lactose, no other allergens are present Whey proteins and caseinates are two major fractions of cow milk proteins.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Water (isovoloumous amount)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Water (isovoloumous amount)
Study: NCT06597422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 Placebo
Description: Eye drop, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, three times daily for a total of 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, three times daily for a total of 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, three times daily for a total of 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, six times daily for a total of 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 Placebo
Description: Eye drop, multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, single dose, tear samples will be collected
Study: NCT06609213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food
Description: Enteral nutrition formula will be used both by mouth and via feeding tube. This product is considered a medical food.
Study: NCT06658431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music group therapy
Description: 90 minutes music group therapy
Study: NCT05969990

Intervention type: OTHER
Intervention: tryptophan metabolites in plasma
Description: we will investigate the tryptophan metabolites in plasma of children with migraine

Intervention type: OTHER
Intervention: tryptophan metabolites in plasma
Description: we will investigate the tryptophan metabolites in plasma of children with migraine
Study: NCT04680533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Quell TENS device. The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
Study: NCT06157411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating Intervention (AC group)
Description: Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Mindful eating program: group sessions one evening a week (8x2h) and home exercises (30 min/day).~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1~Focus groups: Each participant will be asked to describe the program and talk about their perceptions and feelings, as well as the potential changes in behavior they have observed in their daily life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dietetic Intervention (DC group)
Description: Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1
Study: NCT04778839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Micelles for Injection
Description: Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
Study: NCT06657248

Intervention type: DEVICE
Intervention: univation® XF Pro
Description: Primary medial unicompartmental knee arthroplasty
Study: NCT06588608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auricular nerve stimulation (aVNS)
Description: The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auricular nerve stimulation (aVNS)
Description: The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham aVNS
Description: The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham aVNS
Description: The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
Study: NCT05535816

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
Study: NCT06670976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study: NCT06670027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family voice
Description: Group A receives the family voice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nature sound
Description: Group B receives the nature sound.